Ocugen Inc
$ 1.99
3.11%
17 Apr - close price
- Market Cap 652,516,000 USD
- Current Price $ 1.99
- High / Low $ 2.04 / 1.96
- Stock P/E N/A
- Book Value -0.04
- EPS -0.23
- Next Earning Report 2026-05-08
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.63 %
- ROE -7.77 %
- 52 Week High 2.73
- 52 Week Low 0.64
About
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. The company is headquartered in Malvern, Pennsylvania.
Analyst Target Price
$11.57
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-27 | 2025-11-05 | 2025-08-04 | 2025-05-12 | 2025-03-31 | 2024-11-08 | 2024-08-08 | 2024-05-14 | 2024-02-07 | 2023-11-09 | 2023-08-21 | 2023-05-05 |
| Reported EPS | -0.06 | -0.07 | -0.05 | -0.05 | -0.05 | -0.05 | -0.04 | -0.05 | -0.03 | -0.06 | -0.08 | -0.07 |
| Estimated EPS | -0.056 | -0.056 | -0.06 | -0.06 | -0.0533 | -0.05 | -0.05 | -0.06 | -0.06 | -0.07 | -0.07 | -0.11 |
| Surprise | -0.004 | -0.014 | 0.01 | 0.01 | 0.0033 | 0 | 0.01 | 0.01 | 0.03 | 0.01 | -0.01 | 0.04 |
| Surprise Percentage | -7.1429% | -25% | 16.6667% | 16.6667% | 6.1914% | 0% | 20% | 16.6667% | 50% | 14.2857% | -14.2857% | 36.3636% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-08 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.05 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OCGN
2026-04-18 21:08:54
This article reports on Ocugen's stock drop following an update on its gene therapy trial. OCGN shares fell after the company announced an independent data monitoring committee recommended continuing its Phase 1/2 ArMaGMA clinical trial for geographic atrophy without modifications, even though preliminary results showed no unexpected safety concerns but also no clear efficacy signal at the lowest dose level. The trial will now proceed to the second dose level.
2026-04-17 21:10:35
Ocugen (NASDAQ: OCGN) has completed Phase 3 enrollment for its OCU400 gene therapy, with topline data expected in Q1 2027, and reported positive Phase 2 results for OCU410 showing significant lesion reduction in geographic atrophy. The company secured $22.5 million in a direct offering and $15 million from warrant exercises, extending its cash runway into Q1 2027. Ocugen also announced leadership appointments and noted that stockholders will vote on director elections, auditor ratification, executive compensation, advisory vote frequency, and a reverse stock split at the upcoming Annual Meeting on June 11, 2026.
2026-04-17 17:27:00
Ocugen Inc. (OCGN) stock increased by 3.11% on Friday, closing at $1.99 and outperforming the broader market, which also saw gains in the S&P 500 and Dow Jones Industrial Average. Despite the rise, the stock remains 26.97% below its 52-week high of $2.73, achieved on March 17th.
2026-04-17 14:10:08
Ocugen, Inc. plans to submit three Biologics License Applications (BLAs) by 2028 for one-time gene therapies aimed at treating blindness diseases. CEO Dr. Shankar Musunuri highlighted the company's commitment to making advanced therapies, including OCU400, widely accessible. These initiatives are designed to address significant unmet medical needs in eye health and the substantial global burden of vision loss.
2026-04-16 17:29:00
Ocugen Inc. (OCGN) stock fell by 1.03% to $1.93 on Thursday, ending a three-day winning streak. This underperformance occurred despite a positive trading session for the broader market, with the S&P 500 Index and the Dow Jones Industrial Average both seeing gains.
2026-04-16 06:39:56
This article discusses Ocugen Inc. (OCGN), highlighting its popularity among retail investors on platforms like Robinhood. It categorizes OCGN as a penny stock, indicating its low price and potentially high volatility. The piece suggests that such stocks often attract investors looking for significant returns, despite the inherent risks.
